Neurological Biomarkers Market Size, Growth & Statistical Report from 2023 to 2030
In 2022, the global market for neurological biomarkers was assessed at a valuation exceeding USD 7 billion, and it is projected to experience a substantial Compound Annual Growth Rate (CAGR) of approximately 13% throughout the forecast period, which spans from 2023 to 2030. The market’s growth is underpinned by several key factors, including the rising incidence of neurological disorders, advances in technology, the adoption of personalized medicine, increased research and development endeavors, augmented healthcare spending, a supportive regulatory landscape, and collaborative efforts. The expanding population affected by neurological conditions is generating a heightened demand for efficient diagnostic tools.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=98567
Market Trends:
- Rising prevalence of neurological disorders: The prevalence of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and stroke, is increasing worldwide. This is due to a number of factors, including aging population, unhealthy lifestyle choices, and increasing environmental toxins.
- Growing demand for early diagnosis and treatment: Neurological disorders are often difficult to diagnose and treat, and early diagnosis and treatment can lead to better outcomes. Neurological biomarkers can be used to diagnose neurological disorders earlier and more accurately, and to track the progression of these diseases over time.
- Increasing investment in research and development: There is a growing investment in research and development of new neurological biomarkers. This is leading to the development of more accurate and reliable biomarkers, as well as the development of new biomarkers for a wider range of neurological disorders.
- Growing awareness of the benefits of neurological biomarkers: Healthcare professionals and patients are becoming increasingly aware of the benefits of neurological biomarkers. This is leading to an increased demand for biomarker testing and the development of new biomarker-based diagnostic and therapeutic products.
According to the recent report published by RC Market Analytics, the Global Neurological Biomarkers Market is expected to provide sustainable growth opportunities during the forecast period from 2023 to 2030. This latest industry research study analyzes the neurological biomarkers market by various product segments, applications, regions and countries while assessing regional performances of numerous leading market participants. The report offers a holistic view of the neurological biomarkers industry encompassing numerous stakeholders including raw material suppliers, providers, distributors, consumers and government agencies, among others. Furthermore, the report includes detailed quantitative and qualitative analysis of the global market considering market history, product development, regional dynamics, competitive landscape, and key success factors (KSFs) in the industry.
Browse the Full Report Discretion of Global Neurological Biomarkers Market
Geographically, the neurological biomarkers market report comprises dedicated sections centering on the regional market revenue and trends. The neurological biomarkers market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Neurological biomarkers market estimates have also been provided for the historical years 2020 & 2021 along with forecast for the period from 2023 – 2030.The report includes a deep-dive analysis of key countries including the U.S., Canada, the U.K., Germany, France, Italy, China, Japan, India, Australia, Mexico, Brazil and South Africa, among others. Thereby, the report identifies unique growth opportunities across the world based on trends occurring in various developed and developing economies.
The Neurological Biomarkers Market Segmentation:
By Type:
- Genomic
- Proteomic
- Metabolomic
- Imaging
- Others
By Application:
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Autism Spectrum Disorder
- Others
By End-User:
- Hospital & Hospital Laboratories
- Independent Clinical Diagnostic Centers
- Research Organizations and Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Some of the prominent market players operating in the global neurological biomarkers market are Thermo Fisher Scientific, Bio-Rad Laboratories, Siemens Healthineers, Roche Diagnostics, Abbott Laboratories, Biogen, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., and Eli Lilly and Company.
Recent Developments:
- In November 2021, Eisai Co. Ltd. and Biogen Inc. shared findings from the Phase 3 AHEAD 3-45 trial of lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for Alzheimer’s disease. The data highlighted the use of plasma-based biomarkers in assessing the efficacy of lecanemab in clinical trials.
- In October 2021, Diadem made an announcement regarding the release of clinical data showcasing the potential of their AlzoSure biomarker test. The test demonstrated the ability to predict the progression of Alzheimer’s disease several years before the manifestation of symptoms. This could enable early intervention and better management of the disease.
- In 2021, C2N Diagnostics launched PrecivityAD, a blood-based test designed to aid in the early detection of Alzheimer’s disease. The test measures specific blood-based biomarkers, including amyloid beta and tau proteins, which are associated with Alzheimer’s pathology.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=98567
Key Questions Answered by Neurological Biomarkers Market Report:
- Product popularity and adoption based on various country-level dynamics
- Regional presence and product development for leading market participants
- Market forecasts and trend analysis based on ongoing investments and economic growth in key countries
- Competitive landscape based on revenue, product offerings, years of presence, number of employees and market concentration, among others
- Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to Neurological Biomarkers market
- Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2020-2027
About Us: RC Market Analytics is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities to optimize strategies. Our expert’s team of analysts’ provides enterprises with strategic insights. RC Market Analytics works to help enterprises grow through strategic insights and actionable solutions. Feel free to contact us for any report customization at [email protected].
Our Blog: The Pioneer Herald
Media Contact
Company Name: RC Market Analytics Pvt. Ltd.
Contact Person: Vijendra Singh
Email: Send Email
Country: India
Website: https://www.researchcorridor.com/
